Lorenzo M. Pinto

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Real-world effectiveness of topical ruxolitinib in non-segmental vitiligo: repigmentation, mental health, and quality-of-life outcomes in an 860-patient multicentre study.

Journal: The British journal of dermatology

Published: May 16, 2026

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2026

Evaluation of localized scleroderma by line-field confocal optical coherence tomography.

Evaluation of localized scleroderma by line-field confocal optical coherence tomography.

Journal: Italian journal of dermatology and venereology

Published: December 11, 2025

Line Field Confocal Optical Coherence Tomography (LC-OCT) Features of Primary Cicatricial Alopecias.

Line Field Confocal Optical Coherence Tomography (LC-OCT) Features of Primary Cicatricial Alopecias.

Journal: International journal of dermatology

Published: November 15, 2025

Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.

Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.

Journal: American journal of clinical dermatology

Published: November 05, 2025

No Increased Risk of Thromboembolic Events During 6-Month Treatment With Baricitinib in Patients With Alopecia Areata.

No Increased Risk of Thromboembolic Events During 6-Month Treatment With Baricitinib in Patients With Alopecia Areata.

Journal: International journal of dermatology

Published: August 06, 2025

Topical Ruxolitinib as an Effective Therapy for Vitiligo-Like Lesions Induced by Anti-PD-1 Therapy.

Topical Ruxolitinib as an Effective Therapy for Vitiligo-Like Lesions Induced by Anti-PD-1 Therapy.

Journal: International journal of dermatology

Published: July 01, 2025

Elective First-Line Use of Dimethyl Fumarate in Psoriasis: Insights from an Italian Cohort.

Elective First-Line Use of Dimethyl Fumarate in Psoriasis: Insights from an Italian Cohort.

Journal: Dermatology practical & conceptual

Published: June 25, 2025

Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy.

Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy.

Journal: Clinics and practice

Published: June 09, 2025

Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.

Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.

Journal: Skin health and disease

Published: October 02, 2024

Line-field confocal optical coherence tomography in alopecia areata and histopathological correlation.

Line-field confocal optical coherence tomography in alopecia areata and histopathological correlation.

Journal: International journal of dermatology

Published: August 06, 2024

Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.

Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment.

Journal: Expert opinion on drug safety

Published: May 08, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026